Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Common Equity (2023 - 2025)

Historic Common Equity for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to $15.7 million.

  • Mangoceuticals' Common Equity rose 1747.61% to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year increase of 1747.61%. This contributed to the annual value of $13.9 million for FY2024, which is 170007.19% up from last year.
  • Per Mangoceuticals' latest filing, its Common Equity stood at $15.7 million for Q3 2025, which was up 1747.61% from $19.2 million recorded in Q2 2025.
  • Mangoceuticals' 5-year Common Equity high stood at $20.3 million for Q1 2025, and its period low was -$958468.0 during Q1 2024.
  • Moreover, its 3-year median value for Common Equity was $13.6 million (2024), whereas its average is $10.1 million.
  • The largest annual percentage gain for Mangoceuticals' Common Equity in the last 5 years was 221293.86% (2025), contrasted with its biggest fall of 1747.61% (2025).
  • Over the past 3 years, Mangoceuticals' Common Equity (Quarter) stood at $774754.0 in 2023, then surged by 1700.07% to $13.9 million in 2024, then grew by 12.79% to $15.7 million in 2025.
  • Its Common Equity stands at $15.7 million for Q3 2025, versus $19.2 million for Q2 2025 and $20.3 million for Q1 2025.